MDGL

379.1004.45%
MC

Mardi C. Dier

Executive VP & CFO

Ms. Mardi C. Dier serves as a Member of the Board of Managers of HCRx Holdings at HealthCare Royalty Management, LLC. Ms. Dier has served as a member of the board of directors of Healthcare Royalty Partners, a healthcare investment firm, since December 2022. She is member of the Board of Managers since October 2022. Ms. Dier served as a member of the board of directors of Synthekine Inc., a biotechnology company, from May 2021 to June 2025. She served as Chief Financial Officer and Executive Vice President Ultragenyx Pharmaceutical Inc. since October 2020 until November 15, 2022. She serves as Chief Financial Officer at Madrigal Pharmaceuticals, Inc. since March 11, 2024 and is its EVP. She served as SVP at Madrigal Pharmaceuticals, Inc. since March 11, 2024. Ms. Dier served as Independent Director at Synthekine, Inc. since June 2021. She Joined Synthekine, Inc. in June 2021. Ms. Dier has been an Independent Director of ORIC Pharmaceuticals, Inc. since February 2020. She served as a Director of Prelude Therapeutics Inc. since August 2020 until October 17, 2025. She had been the Chief Business Officer and Chief Financial Officer of Acelyrin, Inc. since November 2022 until August 2, 2023. Ms. Dier served as an Executive Vice President of Portola Pharmaceuticals, Inc. since November 2013 and had been its Senior Vice President and Chief Financial Officer from August 2006 to November 2013. Ms. Dier had been Chief Business Officer of Portola Pharmaceuticals, Inc. from August 2006. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, business development, Investor Relations and corporate communications functions. Ms. Dier joined Portola in August 2006 as Senior Vice President and Chief Financial Officer until November 2013. She was an Interim Co-President of Portola Pharmaceuticals, Inc. since June 3, 2018 until October 8, 2018. Ms. Dier has overseen the development of the accounting, finance, global supply chain, Investor Relations, communications, IT and facilities functions. She has several years of financial and Investor Relations experience. She has financial management experience in the biotechnology industry. She served as a Vice President of Investor Relations at Chiron Corporation from 2003 to April 2006. While at Chiron, her responsibilities included developing relationships with Wall Street and communicating Chiron Corporation's financial performance and growth strategy for several commercial products as well as for several pipeline opportunities. Prior to joining Chiron, she served as an investment banker and a director in the west coast life sciences practice at Prudential Securities, where she focused on client development, equity underwriting and mergers and acquisitions. From 1994 to 2001, Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Ms. Dier previously served as a supervising senior accountant at the audit department of KPMG Peat Marwick, from 1986 to 1990. She served as a Director of Adamas Pharmaceuticals, Inc. since October 11, 2017 until June 9, 2021. In 2013, Ms. Dier was recognized as one of the most influential Bay Area businesswomen by the San Francisco Business Times and was a finalist for its Bay Area Chief Financial Officer of the Year Award. Ms. Dier holds an MBA degree from Anderson School at the University of California, Los Angeles and a B.S. degree in Biology from Stanford University.

Positions